We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Feather Safety Razor

Download Mobile App





Discovery of Omicron Neutralizing Antibodies Could Lead to Effective Treatments for COVID-19 Variants

By HospiMedica International staff writers
Posted on 29 Dec 2021
Print article
Illustration
Illustration

An international team of scientists have identified antibodies that neutralize Omicron and other SARS-CoV-2 variants, raising hopes of the findings leading to the development of more effective vaccines and antibody treatments for COVID-19 variants.

In a research project supported by the Howard Hughes Medical Institute (Chevy Chase, MD, USA), researchers identified the antibodies which target areas of the virus spike protein that remain essentially unchanged as the viruses mutate. By identifying the targets of these “broadly neutralizing” antibodies on the spike protein, it might be possible to design vaccines and antibody treatments that will be effective against not only the Omicron variant but other variants that may emerge in the future.

The Omicron variant has 37 mutations in the spike protein, which it uses to latch onto and invade cells. This is an unusually high number of mutations. It is thought that these changes explain in part why the variant has been able to spread so rapidly, to infect people who have been vaccinated and to re-infect those who have previously been infected. The researchers speculate that Omicron's large number of mutations might have accumulated during a prolonged infection in someone with a weakened immune system or by the virus jumping from humans to an animal species and back again.

To assess the effect of these mutations, the researchers engineered a disabled, non-replicating virus, called a pseudovirus, to produce spike proteins on its surface, as coronaviruses do. They then created pseudoviruses that had spike proteins with the Omicron mutations and those found on the earliest variants identified in the pandemic. The researchers first looked to see how well the different versions of the spike protein were able to bind to protein on the surface of cells that the virus uses to latch onto and enter the cell. This protein is called the angiotensin converting enzyme-2 (ACE2) receptor. They found the Omicron variant spike protein was able to bind 2.4 times better than spike protein found in the virus isolated at the very beginning of the pandemic.

The researchers then looked at how well antibodies against earlier isolates of the virus protected against the Omicron variant. They did this by using antibodies from patients who had previously been infected with earlier versions of the virus, vaccinated against earlier strains of the virus, or had been infected and then vaccinated. They found that antibodies from people who had been infected by earlier strains and from those who had received one of the six most-used vaccines currently available all had reduced ability to block infection. Antibodies from people who had previously been infected and those who had received the Sputnik V or Sinopharm vaccines as well as a single dose of Johnson & Johnson had little or no ability to block – or “neutralize” – the Omicron variant's entry into cells. Antibodies from people who had received two doses of the Moderna, Pfizer/BioNTech, and AstraZeneca vaccines retained some neutralizing activity, albeit reduced by 20- to 40-fold, much more than any other variants.

Antibodies from people who had been infected, recovered, and then had two doses of vaccine also had reduced activity, but the reduction was less, about fivefold, clearly demonstrating that vaccination after infection is useful. Antibodies from people, in this case a group of renal dialysis patients, who had received a booster with a third dose of the mRNA vaccines produced by Moderna and Pfizer/BioNTech showed only a 4-fold reduction in neutralizing activity. All but one antibody treatments currently authorized or approved to be used with patients exposed to the virus, had no or had markedly reduced activity against Omicron in the laboratory. The exception was an antibody called sotrovimab, which had a two- to three-fold reduction of neutralizing activity, the study found.

But when they tested a larger panel of antibodies that have been generated against earlier versions of the virus, the researchers identified four classes of antibodies that retained their ability to neutralize Omicron. Members of each of these classes target one of four specific areas of the spike protein present in not only SARS-CoV-2 variants but also a group of related coronaviruses, called sarbecoviruses. These sites on the protein may persist because they play an essential function that the protein would lose if they mutated. Such areas are called “conserved.” The finding that antibodies are able to neutralize via recognition of conserved areas in so many different variants of the virus suggests that designing vaccines and antibody treatments that target these regions could be effective against a broad spectrum of variants that emerge through mutation.

“This finding tells us that by focusing on antibodies that target these highly conserved sites on the spike protein, there is a way to overcome the virus’ continual evolution,” said David Veesler, investigator with the Howard Hughes Medical Institute and associate professor of biochemistry at the University of Washington School of Medicine in Seattle.

Related Links:
Howard Hughes Medical Institute 


Print article
IIR Middle East

Channels

Critical Care

view channel
Image: Three dimensional measurement of the all-mesh thermistor (Photo courtesy of Shinshu University)

Ultraflexible, Gas-Permeable Thermistors to Pave Way for On-Skin Medical Sensors and Implantable Devices

On-skin medical sensors and wearable health devices are important health care tools that must be incredibly flexible and ultrathin so they can move with the human body. In addition, the technology has... Read more

Surgical Techniques

view channel
Image: Engineers have developed a process that enables soft robots to grow like plants (Photo courtesy of University of Minnesota)

Soft Robotic System Can Grow Like Plants to Allow Surgical Access to Hard-To-Reach Areas

Soft robotics is an emerging field where robots are made of soft, pliable materials as opposed to rigid ones. Soft growing robots can create new material and “grow” as they move. These machines could be... Read more

Patient Care

view channel
Image: The biomolecular film can be picked up with tweezers and placed onto a wound (Photo courtesy of TUM)

Biomolecular Wound Healing Film Adheres to Sensitive Tissue and Releases Active Ingredients

Conventional bandages may be very effective for treating smaller skin abrasions, but things get more difficult when it comes to soft-tissue injuries such as on the tongue or on sensitive surfaces like... Read more

Health IT

view channel
Image: Using digital data can improve health outcomes (Photo courtesy of Unsplash)

Electronic Health Records May Be Key to Improving Patient Care, Study Finds

When a patient gets transferred from a hospital to a nearby specialist or rehabilitation facility, it is often difficult for personnel at the new facility to access the patient’s electronic health records... Read more

Business

view channel
Image: Differentiated stapling technology for bariatric surgery (Photo courtesy of Standard Bariatrics)

Teleflex Completes Acquisition of Bariatric Stapling Technology Innovator

Teleflex Incorporated (Wayne, PA, USA), a leading global provider of medical technologies, has completed the previously announced acquisition of Standard Bariatrics, Inc. (Cincinnati, OH, USA), which has... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.